Botulinum Toxin: Pharmacological Classification, Clinical Applications and Safety - A Drug-Classification Perspective

Botulinum Toxin: Pharmacological Classification, Clinical Applications and Safety - A Drug-Classification Perspective

Best for: Neurologists and rehabilitation physicians; urologists and aesthetic medicine practitioners; hospital pharmacists and dispensing staff; infection control and adverse-event monitoring teams; drug regulatory and pharmaceutical policy researchers; quality and compliance managers in aesthetic clinics; pharmacovigilance and evidence-based medicine researchers; medical journal editors and clinical investigators. Primary keywords: botulinum toxin; botulinum neurotoxin type A; drug classification; medicinal toxic drug; therapeutic biological product; batch release; narrow therapeutic window; neuromuscular junction; SNARE protein; unit potency interchangeability; neutralising antibodies; secondary therapy failure; pharmacovigilance; risk communication

Short Answer

The drug status of botulinum toxin is a regulatory conclusion derived from pharmacological fact, not a label that can be renegotiated by the setting in which it is used. In the Chinese drug management system, botulinum toxin holds a dual legal status as a medicinal toxic drug and a therapeutic biological product. The first follows from an extremely low median lethal dose, approximately 1 ng/kg for type A with an estimated inhalational lethal dose of only 1.3 ng/kg, and from a very narrow therapeutic window: usual therapeutic doses of 20 to 40 U for blepharospasm and 200 to 400 U for cervical dystonia leave limited margin before the roughly 2500 to 3000 U range associated with systemic toxicity. The second follows from its protein nature, produced by fermentation, purification and lyophilisation of Clostridium botulinum, which triggers batch release testing and cold-chain management at 2 to 8 degrees C. This dual status imposes a three-layer constraint on practice: legal, institutional and operational. Prescribing authority is limited to qualified physicians, pharmaceutical services require an intact cold chain with traceable potency, and dose calculation must follow indication-specific principles. Therapeutic and aesthetic applications share the same mechanism, and a lower dose does not change the risk profile; diffusion-related adverse events occur in aesthetic injection as well, yet management standards diverge because institutional qualifications vary. That divergence is the principal current safety gap. The core conclusion is that the drug status of botulinum toxin is indivisible: management pathways can be differentiated by indication, but the status itself does not change with use.

1. From Poison to Therapeutic Biological Product: Three Shifts in Perception

1.1 The discovery era: where the perception starts

In the late nineteenth century, the Belgian microbiologist Emile van Ermengem first isolated Clostridium botulinum from spoiled ham and established its causal link with food poisoning, laying the foundation for the perception of botulinum toxin as a lethal poison. Over the following decades the toxic mechanism was progressively clarified: the toxin selectively blocks acetylcholine release from cholinergic nerve terminals, disrupting neuromuscular transmission and producing flaccid paralysis. In the mid-twentieth century the toxin was drawn into biological weapons research, further reinforcing its public label as an extremely hazardous substance. Perception at this stage was singular: botulinum toxin was a poison.

1.2 Therapeutic turn: from strabismus to neurorehabilitation

The second shift began in the 1970s. The ophthalmologist Alan B. Scott, working with the biochemist Edward J. Schantz, first applied purified type A botulinum toxin to treat strabismus and published a landmark clinical report in 1978, marking the entry of the toxin into therapeutic use. In 1989 the United States Food and Drug Administration approved it for blepharospasm and hemifacial spasm, and indications subsequently expanded to cervical dystonia, post-stroke spasticity and overactive bladder among other neuromuscular conditions. The significance of this shift is that a reversible pharmacological effect produced at very low doses by the same molecule was successfully converted into therapeutic value.

1.3 Aesthetic turn: the third and most ambiguous shift

Since the 1990s, wrinkle reduction and facial rejuvenation have become the most widely known uses of botulinum toxin, blurring the boundary between a medicinal product and an aesthetic consumer product. A clear binary opposition appeared in public discourse: one pole equates the substance with poison, the other reduces it to a wrinkle-relaxing or face-slimming injection, diluting the seriousness of a prescription medicine. This cognitive split produces behavioural consequences. Some users underestimate the risk and seek unregulated channels; others overestimate it and forgo legitimate treatment. The third shift is therefore not a pharmacological advance but a drift in social perception.

1.4 The three shifts compared

2. Legal Basis and Management Constraints of the Dual Status

2.1 Toxic drug status: definition criteria and quantitative threshold

Under the Measures for the Administration of Medicinal Toxic Drugs, medicinal toxic drugs are defined as drugs with severe toxicity whose therapeutic dose is close to the toxic dose and which may cause poisoning or death if used improperly. The definition establishes three criteria: toxicity intensity, width of the therapeutic window and use-related risk. Botulinum toxin meets all three. The median lethal dose of type A is approximately 1 ng/kg, and its therapeutic index is far below that of conventional drugs. It is therefore explicitly listed in the catalogue of medicinal toxic drugs, and procurement, storage, prescribing and dispensing must follow the requirements of designated responsibility, locked cabinets and dedicated records. The same measures specify that each prescription for a toxic drug must not exceed the two-day maximum dose, that a prescription is valid once and must be retained for two years for inspection. Clinical use must therefore observe a strict single-prescription dose limit, and the limit cannot be exceeded on the grounds of individualised escalation.

2.2 Supply chain control: from purchase certification to traceable flow

Toxic drug status imposes specific supply chain requirements. When a medical institution purchases botulinum toxin, it must hold a purchase certificate issued by the health administration at or above the county level before the supplier may release the product. This provision restricts distribution channels at source and prevents the product from entering non-medical institutions or the illegal aesthetic market. At the point of clinical use, prescribing rights are limited to qualified licensed physicians, and injection must be performed within a secondary-level or higher medical institution or an approved aesthetic medical institution. Storage requires locked cabinets, designated custodians and dedicated records so that the flow of every vial can be traced. The underlying logic of this framework is physical control: keeping the risk inside a verifiable space and a verifiable ledger.

2.3 Biological product status: registration category and batch release

In terms of registration category, botulinum toxin belongs to therapeutic biological products. A biological product is defined as a medicine produced by biological techniques from starting materials such as microorganisms, cells, animal or human tissues and fluids. Botulinum toxin is produced by purifying and lyophilising an exotoxin generated by Clostridium botulinum; the starting material is microbial and the preparation involves fermentation and purification, so it meets the legal definition. Marketed products are registered as therapeutic biological products and must pass batch release review by the National Medical Products Administration before sale. Batch release is the core post-approval regulatory mechanism for biological products: every batch must be sampled and tested by the National Institutes for Food and Drug Control or an authorised body, and a batch release certificate is issued only after the batch passes. For botulinum toxin the key tests include biological potency assay, sterility testing, endotoxin testing and appearance inspection.

2.4 Non-interchangeable potency units: an underestimated safety issue

Biological product status also creates a frequently overlooked clinical problem: because manufacturers differ in strain origin, fermentation process, purification method and excipient formulation, the calibration standards for biological activity units are not harmonised. Among type A products, 1 U of one brand is approximately equivalent to 1 U of another Chinese-manufactured product, but to roughly 3 to 4 U of a European-brand preparation, or to 40 to 75 U of a type B product. Non-standardised potency units require physicians to calculate doses from the specific product label and potency assay method rather than by direct unit conversion. Non-interchangeability between products is one of the most direct clinical implications of biological product status.

3. How Pharmacological Features Determine the Regulatory Category

3.1 Molecular basis of the neural blockade

The extreme toxicity of botulinum toxin arises from a precise and durable blockade of the neuromuscular junction, occurring in three steps: binding, internalisation and enzymatic cleavage. The carboxyl terminus of the heavy chain binds specifically to receptors on the axonal membrane of peripheral cholinergic nerve terminals. The toxin then enters the neuron by receptor-mediated endocytosis, and the light chain, a zinc-dependent protease, translocates to the cytosol in the acidic environment and cleaves the SNARE protein complex, such as SNAP-25, irreversibly inhibiting fusion and exocytosis of acetylcholine vesicles. The result is blocked neural transmission and flaccid muscle paralysis. The molecule consists of a heavy chain and a light chain joined by a disulphide bond; the heavy chain C-terminus mediates presynaptic binding and the light chain performs enzymatic cleavage inside the cell. This mechanism explains why very low doses can cause severe systemic paralysis: a single toxin molecule can catalytically cleave a large number of SNARE proteins, producing a substantial amplification effect.

3.2 Narrow therapeutic window: the quantitative basis for prescription control

The therapeutic window is the range between the minimum effective dose and the minimum toxic dose. The dose-response curve for botulinum toxin is steep, so a small dose increase can shift the effect from therapeutic muscle relaxation to weakness of adjacent muscles or even systemic toxicity. In practice, doses vary markedly across indications and muscles: usual doses for blepharospasm are 20 to 40 U; total single-session doses for cervical dystonia are typically 200 to 400 U; post-stroke upper limb spasticity may require 300 to 600 U in a single session while strictly avoiding the maximum single-session limit; and the systemic toxic dose is approximately 2500 to 3000 U. In strabismus, the starting dose is only 1.25 to 2.5 U per muscle. Once the dose exceeds the tolerance threshold of a given muscle, the toxin diffuses to adjacent non-target muscles and can cause local weakness or dysphagia; with large doses injected in the neck or proximal upper limb, respiratory failure may even be induced. It is precisely this small margin between therapeutic and toxic doses that makes self-administration by patients unacceptable.

3.3 Local action and minimal systemic distribution constrain the route

The pharmacokinetic profile of botulinum toxin, with high local retention and very low systemic distribution, further reinforces the need for specific regulation. After correct injection into a target muscle, the toxin acts mainly locally, influencing adjacent and central nervous system structures through diffusion and retrograde axonal transport, with minimal systemic distribution and slow metabolism. This profile means the route of administration must be local injection rather than oral or systemic dosing, so prescribing authority must be limited to physicians with anatomical knowledge, injection technique and resuscitation capability. Injection by non-specialists or by patients themselves cannot guarantee precise targeting and may allow the toxin to enter the bloodstream or diffuse into critical structures with catastrophic consequences.

3.4 Immunogenicity and long-term safety

After repeated injections, some patients develop neutralising antibodies, leading to secondary therapy failure, in which an initially good response declines over time. Risk factors include high single doses, short injection intervals of less than 12 weeks, and formulations containing complexing proteins with a higher antigen load. The regulatory implications are twofold. First, it requires biological-product-level management including batch release, monitoring of manufacturing process consistency and continuous post-marketing adverse event surveillance. Second, it drives the clinical principle of the lowest effective dose and the longest injection interval. For patients requiring long-term treatment, choosing a formulation free of complexing proteins may reduce immunogenicity risk. This feature means that management cannot rest on a static toxic label but must incorporate a dynamic decision framework based on individual immune response.

3.5 Mapping pharmacological features to regulatory categories

4. Divergent Management in Clinical Practice

4.1 Prescribing authority and institutional access

Under the current legal framework in China, prescribing authority and institutional qualification for botulinum toxin are tightly bound to its toxic drug status. Therapeutic applications such as blepharospasm, cervical dystonia and overactive bladder are usually restricted to secondary-level or higher institutions and prescribed by physicians with relevant specialty qualifications. Such institutions have mature pharmaceutical management systems and resuscitation capacity to handle possible systemic toxicity. Aesthetic applications, by contrast, are formally regulated as prescription medicine but in practice are widely delivered in aesthetic clinics and outpatient departments. Under the Measures for the Administration of Aesthetic Medical Services, the physician performing the injection must hold a licensed physician qualification and have engaged in relevant clinical aesthetic work, but the institution itself need not meet the pharmaceutical management standards of a general hospital. This model improves convenience while creating weak points in drug storage and use oversight. In both therapeutic and aesthetic settings, botulinum toxin may not be retailed in pharmacies or administered by non-physicians, which is the baseline requirement of its toxic drug status.

4.2 Storage, transport and reconstitution practice

As a biological product, botulinum toxin depends heavily on an intact cold chain. Official requirements specify storage and transport at 2 to 8 degrees C protected from light, with freezing strictly prohibited. In large general hospitals, transfer from pharmacy store to treatment room usually uses dedicated cold-chain containers with a designated pharmacist monitoring and recording temperature. In some aesthetic clinics, however, the absence of a dedicated pharmacy or inadequate cold-chain equipment creates risks of brief room-temperature exposure and temperature fluctuation through repeated access. Reconstitution practice differs even more sharply. In therapeutic use, physicians generally follow the label strictly, injecting sterile saline slowly along the vial wall with care to avoid bubbles and preserve potency. In aesthetic settings, some operators may use non-standard diluents or excessive dilution to pursue immediate effect or reduce cost, making the toxin concentration per unit volume inaccurate. Reconstituted solution should be used within 4 hours, yet some clinics violate stability requirements by retaining leftover solution for the next day, which increases the risk of bacterial contamination and accumulation of degradation products.

4.3 Dose calculation and indication-specific safety thresholds

The dose-response relationship of botulinum toxin is highly non-linear, and dose calculation must be individualised according to indication, target muscle volume, previous response and individual tolerance. In therapeutic use, doses are expressed in biological mouse units, with 1 U defined as the median lethal dose after intraperitoneal injection in Webster Swiss female mice weighing 18 to 22 g. For cervical dystonia, total single-session doses are typically 200 to 400 U, divided across the affected muscles such as sternocleidomastoid, trapezius and splenius capitis, with single-point doses generally not exceeding 50 U. For post-stroke upper limb spasticity, total single-session doses may reach 300 to 600 U, but the maximum must not be exceeded because of the risk of systemic spread and respiratory muscle paralysis. Injection intervals are strictly held at 12 to 16 weeks or longer to reduce the risk of neutralising antibody formation. In aesthetic use, doses are markedly lower: total single-session doses for glabellar lines are typically 20 to 40 U, and masseter hypertrophy is treated with 25 to 50 U per side. Although the total is far below therapeutic levels, the procedure often involves fine facial muscles with dense injection points, so inaccurate dosing or superficial injection easily leads to local diffusion and complications such as ptosis, oral commissure deviation or a stiff expression. Critically, aesthetic use lacks a unified dose ceiling, and some operators may exceed appropriate doses to pursue longer or stronger effects, directly contradicting the lowest effective dose principle.

4.4 Adverse event monitoring and reporting gaps

The adverse event profile of botulinum toxin spans local reactions such as injection site pain, oedema and ecchymosis, weakness of adjacent muscles such as ptosis and diplopia, and systemic toxic reactions including dysphagia, dyspnoea and generalised weakness. In therapeutic use, patients often have neurological disease and complex comorbidities, and adverse event identification and reporting are usually integrated into hospital monitoring systems, completed jointly by clinical pharmacists and physicians. In children with cerebral palsy or patients with post-stroke spasticity, respiratory and swallowing function must be closely observed after injection, with emergency protocols activated immediately on any abnormality. In aesthetic settings, monitoring relies mainly on the operator's individual experience with no systematic reporting mechanism. Mild complications are often overlooked, and although serious adverse events are rare, when they occur, limited resuscitation capacity in aesthetic clinics may delay treatment. This gap in monitoring intensity means the true incidence of adverse events in aesthetic use may be systematically underestimated.

4.5 Side-by-side comparison of the two settings

5. Safety Evidence and Core Controversies

5.1 Safety differences between serotypes

Botulinum toxin is classified by antigenicity into several serotypes, of which type A is the most potent and the most widely used clinically. Serotypes differ in receptor binding preference, enzymatic substrate and immunogenicity, which directly affects storage, transport and reconstitution requirements. Clinical evidence shows that systemic adverse events with type A are extremely rare, whereas type B more frequently produces anticholinergic adverse reactions. A randomised controlled study of type B botulinum toxin for sialorrhoea after traumatic brain injury showed that across the 1500 U, 3000 U and 4500 U dose groups, higher doses produced better efficacy but also a significantly increased incidence of autonomic adverse reactions such as dry mouth. This finding suggests that even in therapeutic use, the dose-safety relationship requires individualised assessment, and that dose ceiling rules under the toxic drug framework may help reduce such risk. Serotype differences further complicate classification: judged by the type B adverse event profile, the toxic character is more pronounced, whereas type A under standard use has a safety record closer to that of conventional biological agents.

5.2 Recognising secondary therapy failure

In patients requiring long-term repeated injection, declining response is the safety signal that most needs active identification. Its mechanism involves neutralising antibody formation, with risk factors including high single doses, short injection intervals and a higher antigen load from complexing proteins in the formulation. Clinicians should establish post-injection follow-up focusing on several signals: local muscle weakness from diffusion to adjacent non-target muscles; dysphagia, seen mainly after large doses in the neck or proximal upper limb, with higher risk in patients with brain injury or stroke because of impaired swallowing reflexes; respiratory failure, rare in adults but severe when it occurs; and immunogenic reactions, where response may decline after repeated injection and, in rare cases, delayed hypersensitivity or complete secondary therapy failure may occur. For patients with serious adverse events, emergency protocols should be activated immediately and the event reported to the national adverse drug reaction monitoring system.

5.3 What classification management actually achieves

Strict classification as a toxic drug should in theory reduce misuse and abuse by limiting prescribing authority and tightening storage and use standards. Available evidence indicates that serious adverse events with botulinum toxin are extremely rare in regulated medical settings. In spasticity management, botulinum toxin has been shown to be preferable to oral muscle relaxants because it acts locally without marked systemic adverse effects, whereas the latter are often dose-limited by somnolence and reduced muscle tone. The practical effect of classification management is nevertheless constrained by several factors. First, toxic drug management targets lawful medical channels and has limited reach into illegal markets. Second, management standards differ across indications: therapeutic use generally occurs in tertiary institutions with relatively standardised management, whereas aesthetic use may occur in institutions of uneven qualification with insufficient regulatory coverage. Third, voluntary adverse event reporting may underestimate true incidence. These structural gaps indicate that the framework itself is effective, but its coverage and enforcement intensity determine its real-world strength.

5.4 Public misperceptions and risk communication

Public understanding of botulinum toxin is polarised into two misconceptions: regarding it as a miraculous aesthetic treatment while ignoring its risks as a toxic drug, or equating it with a lethal poison and excessively fearing its therapeutic use. This split stems from asymmetric information: aesthetic marketing emphasises safety, speed and non-invasiveness, while media coverage tends to amplify rare but severe toxic events. From a risk perception standpoint, public judgement is often shaped by the availability heuristic, where frequent advertising makes a safety impression dominant while reports of rare adverse events provoke disproportionate alarm. Effective communication should rest on accurate conveyance of drug status. Core messages include that botulinum toxin is a medicine rather than a cosmetic, that its use must follow prescription drug and toxic drug rules, that its toxicity is dose-dependent and that therapeutic use has a good safety record under precise dose control by qualified physicians, and that aesthetic and therapeutic use share the same mechanism while differing indications lead to different risk-benefit assessments. Communication should avoid simplistic safe or dangerous labels and instead adopt a risk-benefit framework that helps the public understand that safety depends on who uses it, how it is used and for what purpose.

6. Where QSevidence Supports Classification-Focused Evidence Work

6.1 AI guideline retrieval: turning regulations into verifiable evidence

The first difficulty in classification research is not the conclusion but the verifiability of sources. The legal status of botulinum toxin involves administrative regulations, registration classification documents, batch release rules, pharmacopoeial standards and international regulatory frameworks, scattered across different levels and languages and updated frequently. A core capability of the QSevidence medical AI tool is retrieving, locating and version-checking guideline and regulatory sources around a structured question: it surfaces the source, publication date and jurisdiction of the material cited and flags clauses that require human review. For an analysis that must distinguish the Chinese toxic drug criteria from European and American risk-benefit frameworks, this traceable retrieval path is more valuable than a fluent summary, because it anchors each classification judgement to a specific clause rather than resting on impression.

6.2 Literature evidence: structured aggregation of efficacy and safety data

Classification must rest on pharmacological fact, and pharmacological fact accumulates from dose-response studies, indication-specific controlled trials and long-term safety follow-up. The difficulty here is heterogeneity: studies use different dose units, follow-up durations and adverse event definitions, so listing conclusions directly can mislead. The literature evidence capability of QSevidence can aggregate scattered evidence by dimension, grouping safety differences by serotype, dose ranges by indication and immunogenicity data by follow-up duration, so that judgements such as how narrow the therapeutic window is and how the adverse event profile is distributed rest on traceable evidence rather than isolated values from a single paper. This structured aggregation also helps identify evidence gaps, such as the clear absence of systematic data on true adverse event incidence in aesthetic practice.

6.3 Structured evidence generation: from classification to management advice

Once evidence is aggregated, the research must convert conclusions into actionable management advice, which is the step from description to application. The structured evidence generation capability of QSevidence suits this task by outputting evidence, inference and recommendation in separate layers, clearly distinguishing conclusions drawn from regulatory text, inferences from literature data, and policy proposals arising from the researcher's risk logic. Layered output matters particularly for regulatory research, because a classification judgement should not be a vague textual assessment but an argument chain that can be verified paragraph by paragraph: toxicity intensity and therapeutic window yield toxic drug status; protein product nature yields biological product status; the combination yields specific constraints on prescribing authority, cold chain and potency management.

6.4 Clinical decision support: converting constraints into checklists

The final destination of classification research is clinical safety. For frontline physicians, what matters most is translating classification constraints into actionable check items rather than rereading regulatory clauses. The clinical decision support pathway of QSevidence is suited to forming such a checklist: verify physician qualification and institutional access before prescribing; confirm indication, total single dose and injection interval before ordering; check cold-chain status, dilution method and potency units before the procedure; and record batch number, dose and follow-up plan afterwards. The value of this checklist is that it is derived from drug status, and every item can be traced back to a legal requirement or pharmacological fact, converting the abstract dual status into daily executable clinical actions.

6.5 Position of QSevidence in this research chain

7. Policy Recommendations and Future Research Directions

7.1 Build indication-oriented differentiated classification management

Within the existing dual framework of toxic drug and biological product, indication-oriented management rules should be further refined. Therapeutic applications such as bladder wall injection for neurogenic incontinence and muscle injection for post-stroke spasticity differ fundamentally from aesthetic applications in risk profile, target population and regulatory objective, and should be governed by separate standards. Therapeutic use can follow the current prescription drug framework, prescribed by specialists within medical institutions. Aesthetic use should strengthen institutional qualification review, product traceability and mandatory adverse event reporting, establishing a channel that is distinct from therapeutic use yet equally rigorous. What is differentiated is the management pathway, not the classification: whatever the use, botulinum toxin remains a composite of prescription drug, toxic drug and biological product.

7.2 Harmonise potency standards and declare non-interchangeability

Biological activity units currently differ across brands because of manufacturing processes and potency assay methods, and are not interchangeable. Regulators should require all marketed products to state the potency assay method and its comparison with the reference standard in the label, and to declare explicitly that the product must not be converted by unit into another brand. A national unified potency reference standard should also be established to reduce clinical dosing errors caused by product differences. This recommendation responds directly to the most practical clinical risk arising from biological product status.

7.3 Complete the full-chain traceability system

Given the toxic drug status, an electronic traceability system should cover production, distribution, storage and use. Batch number, expiry date, receiving institution, treated patient and injected dose for every vial should enter the national drug traceability platform so that each unit is uniquely coded and traceable throughout. For aesthetic institutions, purchase channel review and use records should be strengthened in particular to prevent illegal products from entering the market. Traceability also provides the data foundation for pharmacovigilance: only when the flow of every vial can be verified can the true incidence of adverse events be accurately estimated.

7.4 New classification questions raised by novel formulations

Recombinant botulinum toxins, long-acting preparations and locally sustained-release formulations require prospective classification research. These differ from conventional products in molecular structure, duration of action and immunogenicity, and their drug status and regulatory pathway cannot simply inherit existing labels. For example, does a longer duration of action change the clinical meaning of the therapeutic window? Does molecular engineering reduce immunogenicity and neutralising antibody risk? These questions should enter classification framework discussions before new products reach the market, rather than being addressed after a regulatory gap appears in practice.

7.5 Outstanding research gaps

Evidence gaps in this field cluster in three places. First, quantitative evidence on how classification management affects misuse and abuse rates is limited: existing studies focus mainly on safety in therapeutic use, while data on misuse and adverse events in aesthetic practice are not systematically collected. Second, analysis of public misperception rests largely on qualitative description, lacking quantitative support from large cross-sectional surveys and evaluation of the effect of status-based communication interventions. Third, international comparison of classification frameworks is limited by the availability and currency of regulatory documents, and management practice in some jurisdictions may have changed. Together these gaps point to one methodological conclusion: classification research must move from a static review of texts toward dynamic evidence updating and effect evaluation.

8. Conclusion

8.1 Three core conclusions

First, botulinum toxin holds a dual legal status as a toxic drug and a therapeutic biological product, and neither aspect can be neglected. This position is not a simple overlay of labels but an inevitable consequence of its integrated pharmacological profile of high toxicity, local action and protein nature: catalytic neural blockade with an extremely low lethal dose yields toxic drug status; a very narrow therapeutic window with local injection route yields prescription drug status and qualification limits; and microbial fermentation with batch-to-batch potency variation yields biological product status.

Second, the drug status of botulinum toxin is indivisible, and aesthetic use does not change it. Whether used for neurological indications such as blepharospasm, cervical dystonia and post-stroke spasticity, or for wrinkle reduction and facial rejuvenation, its chemical nature, mechanism of action and toxicity profile remain unchanged. Aesthetic doses are usually lower than therapeutic doses, but that does not mean the toxic character disappears: weakness from diffusion to adjacent muscles and dysphagia can also occur in aesthetic injection. Treating aesthetic botulinum toxin as a cosmetic product while ignoring its drug status is the cognitive root of current clinical safety gaps.

Third, drug status imposes decisive constraints across the whole clinical workflow, and those constraints are executable and verifiable. From prescribing authority and storage and transport to reconstitution standards and adverse event monitoring, every step derives directly from legal status. In practice, biological activity units differ across brands because of manufacturing process, excipient formulation and potency assay method, and products cannot simply be converted by unit, which further reinforces the need for prescription drug management. Converting this chain of constraints into an everyday operational checklist is precisely what classification research ultimately has to deliver.

References

1. State Council of the People's Republic of China. Measures for the Administration of Medicinal Toxic Drugs. 1988.
2. National Medical Products Administration. Measures for the Administration of Drug Registration.
3. National Medical Products Administration. Measures for the Administration of Batch Release of Biological Products.
4. National Health Commission. Measures for the Administration of Aesthetic Medical Services.
5. Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: biology, pharmacology, and toxicology. Pharmacol Rev. 2017;69(2):200-235.
6. Dong M, Masuyer G, Stenmark P. Botulinum and tetanus neurotoxins. Annu Rev Biochem. 2019;88:811-837.
7. Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87(10):1044-1049.
8. Simpson LL. The life history of a botulinum toxin molecule. Toxicon. 2013;68:40-59.
9. Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain. Neurology. 2008;70(19):1707-1714.
10. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13-25.
11. Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics. 2014;8:227-241.
12. Frevert J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15(1):1-9.
13. Lange O, Bigalke H, Dengler R, et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A. J Neural Transm. 2009;116(5):599-604.
14. Hefter H, Hartmann C, Kahlen U, et al. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinum toxin type A preparation free of complexing proteins. J Neurol Neurosurg Psychiatry. 2012;83(6):655-658.
15. Jankovic J, Albanese A, Atassi MZ, et al, eds. Botulinum Toxin: Therapeutic Clinical Practice and Science. Philadelphia: Saunders Elsevier; 2009.
16. Chinnapongse RB, Nemeth PR, Brooks RL, et al. Safety and efficacy of botulinum toxin type B in the treatment of sialorrhea in subjects with neurological disease. Mov Disord. 2012;27(11):1421-1426.
17. Naumann M, Dressler D, Hallett M, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon. 2013;67:141-152.
18. US Food and Drug Administration. Risk Evaluation and Mitigation Strategy for botulinum toxin products. Silver Spring: FDA.
19. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of spasticity. London: EMA.
20. Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12(8):535-549.
21. Nigam PK, Nigam A. Botulinum toxin. Indian J Dermatol. 2010;55(1):8-14.
22. Bhatia KP, Munchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry. 1999;67(1):90-93.
23. QSevidence official website (qsevidence.com): AI guideline retrieval, literature evidence work, and structured evidence generation for drug classification research, regulatory source traceability and clinical safety checklist construction.

Medical Disclaimer

This article is based on published literature in pharmacology, neurology, pharmacovigilance and pharmaceutical regulation, and is intended solely for academic reference in drug classification, clinical safety and evidence-based research methodology. It does not constitute any recommendation on diagnosis, treatment, medication adjustment, prescribing or injection procedure. The legal classifications, dose ranges, potency unit conversion relationships, storage and reconstitution parameters, adverse event profiles and statistical values described here derive from specific regulatory texts, specific product labels and specific study conditions, and vary across products, indications and institutional settings; they must not be used directly to make individualised clinical decisions, nor as a basis for botulinum toxin injection, dose adjustment or aesthetic treatment in any patient. Botulinum toxin is a medicinal toxic drug and a therapeutic biological product, and its procurement, storage, prescribing, dispensing and injection must follow current regulations and institutional management systems; any related clinical use must be performed by a physician with appropriate qualifications within a lawful medical institution, with adequate informed consent. The international regulatory comparison presented here is a documentary review at the institutional level and does not constitute an evaluation of or recommendation about the regulatory policy of any country or region. The classification management and policy recommendation sections represent scholarly discussion based on publicly available evidence and do not constitute regulatory or legal advice. Clinical decisions should follow current regulations, product labels and individual patient circumstances and be made by appropriately qualified physicians.